Solid organ transplantation (SOT) represents one of modern medicine's most profound achievements, offering a life-altering solution for patients suffering from end-stage organ failure. The success of SOT hinges on a complex pharmacological intervention: chronic immunosuppression, meticulously designed to quell the recipient's immune system and prevent the rejection of the transplanted organ. While this therapeutic necessity is paramount for graft survival, it concurrently establishes a unique immunological milieu within the recipient, one that significantly heightens their vulnerability to a spectrum of de novo malignancies. This increased oncogenic risk is not merely a theoretical concern; it is a well-documented epidemiological reality, with transplant recipients exhibiting significantly higher incidence rates for certain cancers compared to the general population. These include, but are not limited to, non-melanoma skin cancers, post-transplant lymphoproliferative disorder (PTLD), Kaposi sarcoma, and anogenital cancers. Understanding the multifaceted nature of this increased risk is crucial for optimizing patient care. It necessitates a deep dive into the intricate interplay between the host immune system, the effects of immunosuppressive agents, and the reactivation or persistence of oncogenic viruses. This book is dedicated to unraveling this complex "immunosuppression-cancer axis" within the transplanted host. We aim to provide a comprehensive overview, bridging fundamental scientific principles with practical clinical applications. Our journey will begin by establishing the baseline vulnerability of the transplanted recipient, exploring the diminished capacity of their compromised immune system to perform its crucial role in cancer surveillance. We will then systematically examine the diverse oncological landscape that emerges post-transplantation, detailing the epidemiology and characteristics of the most prevalent malignancies. The core of our exploration will focus on the mechanistic underpinnings, dissecting how specific immunosuppressive drugs and the reactivation of oncogenic viruses like Epstein-Barr virus (EBV), human papillomavirus (HPV), and human herpesvirus-8 (HHV-8) contribute to oncogenesis. Subsequently, we will pivot to proactive strategies, investigating pharmacological interventions and non-pharmacological measures designed to mitigate cancer risk. The critical role of vigilant monitoring and early detection will be highlighted, followed by a detailed discussion on the management of established cancers in this complex patient population. Finally, we will look towards the future, considering special populations, emerging research, and the evolving landscape of transplant oncology. This book is intended for the dedicated clinicians and researchers at the forefront of transplantation and oncology, serving as a vital resource for enhancing the long-term health and well-being of organ transplant recipients by proactively addressing the significant challenge of post-transplant malignancy.
